Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
At Rajiv Gandhi Government General Hospital, new web portal gives doctors quick access to lab reports
RGGGH biochemistry lab reduces patient queues with web portal, bar code system, point-of-care testing, and therapeutic drug ...
Prioritizing vaccine boosters for vulnerable patients could prevent emergence of new COVID variants
Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine ...
pharmaphorum7h
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
Vietnam Investment Review on MSN18h
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Armed robbery in Revesby3h
Prioritize Boosters for Vulnerable, Prevent New Variants
Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine ...
Armed robbery in Revesby2h
Prioritise Boosters for Vulnerable, Say Scientists
Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the ...
Le Lézard9h
HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding to Advance Treatment for Aggressive Solid Tumors
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, chronic and age-associated diseases, announced that it has ...
PipelineReview.com14h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
News Medical on MSN13h
New immune map uncovers key pancreatic cancer insights
Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...
eLife22h
Enalapril mitigates aging by targeting antioxidative genes via phosphorylated Smad1/5/9
In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...
Medscape9h
Pause Immunosuppressants Prior to Patch Testing If Possible
Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...